
In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.
Learn from Drs. Buchheit and Wagenmann as they discuss key patient traits that predict disease recurrence in CRSwNP.
This infographic explores the emerging concepts of disease activity, disease stability, and disease control in COPD.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Thomas Bieber discusses emerging evidence that therapy-free disease control may be possible in atopic dermatitis, citing pediatric dupilumab data showing that a subset of patients-maintained remission after treatment discontinuation.
Dr. Jean-David Bouaziz highlights a study describing barriers to initiating advanced systemic therapy for AD at EADV 2025

Dr Mario Castro explains how type 2 cytokines play a crucial role in airway remodeling and inflammation in asthma and COPD, impacting patient outcomes.

Watch as Drs. Michihiro Hide, Marta Ferrrer, and Ana M. Giménez-Arnau discuss chronic spontaneous urticaria (CSU) and highlight the unmet needs, importance of disease control, and emerging therapies.

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression

Explore the role of chronic type 2 inflammation in the cycle of exacerbations and worsening lung function in patients with asthma.

Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.
Dr. Evan Dellon discusses the clinical implications of gaps in medical care on the risk of fibrotic progression in EoE.